From: Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers
Group | Control # (%) 36(100%) | No Nodules # (%) 35(100%) | Solid Nodules # (%) 55(100%) | GGO # (%) 46(100%) | Cancer # (%) 22(100%) |
---|---|---|---|---|---|
Male | 16(44.4%) | 15(42.9%) | 22(40%) | 18(39.1%) | 11(50%) |
Female | 20(55.6%) | 20(57.1%) | 33(60%) | 28(60.9%) | 11(50%) |
Cancer on follow up | NA | 0(0%) | 0(0%) | 5(10.9%) | 0(0%) |
SN or GGO Resolved | NA | 0(0%) | 5(9.1%) | 6(13%) | 0(0%) |
Emphysema on CT | NA | 11(31.4%) | 17(30.9%) | 21(45.7%) | 9(40.9%) |
Pleural Plaque(s) | NA | 2(5.7%) | 6(10.9%) | 3(6.5%) | 0(0%) |
Fibrosis | NA | 2(5.7%) | 3(5.5%) | 2(4.3%) | 0(0%) |
Diabetes | NA | 3(8.6%) | 8(14.5%) | 5(10.9%) | 2(9.1%) |
Rheumatoid Arthritis | NA | 0(0%) | 2(3.6%) | 1(2.2%) | 1(4.5%) |
Lupus | NA | 0(0%) | 0(0%) | 0(0%) | 1(4.5%) |
IBD | NA | 0(0%) | 1(1.8%) | 1(2.2%) | 1(4.5%) |
Psoriasis | NA | 0(0%) | 2(3.6%) | 1(2.2%) | 0(0%) |
HIV | NA | 0(0%) | 0(0%) | 1(2.2%) | 0(0%) |
Thyroid Disease | NA | 2(5.7%) | 8(14.5%) | 6(13%) | 3(13.6%) |
Hepatitis | NA | 1(2.9%) | 2(3.6%) | 4(8.7%) | 1(4.5%) |
Bronchiectasis | NA | 0(0%) | 4(7.3%) | 3(6.5%) | 1(4.5%) |
Bronchiolitis | NA | 0(0%) | 2(3.6%) | 3(6.5%) | 0(0%) |
Diffuse Nodular Disease | NA | 0(0%) | 2(3.6%) | 2(4.3%) | 0(0%) |
Pneumonia | NA | 0(0%) | 0(0%) | 3(6.5%) | 0(0%) |
Possible concurrent malignancy | NA | 0(0%) | 3(5.5%) | 3(6.5%) | 2(9.1%) |